Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Download Data

Immix Biopharma Inc Capital Expenditures 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 565.14%

Immix Biopharma Inc Capital Expenditures 3 year CAGR is 565.14% for the Trailing 12 Months (TTM) ending March 31, 2024. Capital Expenditures represent the amount of money spent on acquiring or improving long-term assets, such as property, plant, and equipment. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Immix Biopharma Inc Capital Expenditures for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -0.00, a 100.00% change year over year.
Immix Biopharma Inc Capital Expenditures for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -1.20 K, a 0.00% change year over year.
Immix Biopharma Inc Capital Expenditures for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -1.20 K.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends